

Literaturliste der wissenschaftlichen Veröffentlichungen (nur Peer-reviewed Journals) von Prof. Dr. J.Braun von 1991 bis 2016

Stand: 15.3.2016

1. Braun J, Schneider M, Lakomek HJ. Cornerstones of quality assurance in medicine in Germany : Important impulse for the situation in treatment of rheumatism. *Z Rheumatol* 2016 Mar 3. [Epub ahead of print]
2. Braun J, Baraliakos X, Hermann KA, Xu S, Hsu B. Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab. *J Rheumatol* 2016 Mar 1 [Epub ahead of print]
3. Krause D, Gabriel B, Herborn G, Braun J, Rau R. Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis. *Clin Rheumatol* 2016 Feb 26. [Epub ahead of print]
4. Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M; ASAS. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. *Ann Rheum Dis*. 2016 Feb 10. [Epub ahead of print]
5. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariago IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther* 2016 Jan 20; 18(1): 25
6. Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KA, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Østergaard M, Poddubnyy D, Reijnierse M, van den Bosch F, van der Horst-Bruinsma I, Landewé R. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. *Ann Rheum Dis* 2016 Jan 14. [Epub ahead of print]
7. Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. *Ann Rheum Dis*. 2016 Jan 14. [Epub ahead of print]
8. Braun J, Robbers J, Lakomek HJ. Quality of German medical services: a review. *Z Rheumatol*. 2016 Jan 7. [Epub ahead of print]
9. Paternmann J, Ehlebracht-König I, Lind-Albrecht G, Genth E, Reusch A, Küffner R, Müller-Ladner U, Braun J. EULAR recommendations for patient education of people with inflammatory arthritis : Translation and evaluation in Germany. *Z Rheumatol* 2016 Jan 7. [Epub ahead of print]
10. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofo S, and Richards HB for the MEASURE 1 and

- MEASURE 2 Study Groups. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med* 2015; 373:2534-2548 [Epub December 24, 2015]
11. Tälli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Cañete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, Kalyoncu U, Kiltz U, Maccarone M, Niedermayer D, Otsa K, Scrivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L. Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. *Joint Bone Spine* 2015 Dec 8 [Epub ahead of print]
 12. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis* 2015 Dec 7 [Epub ahead of print]
 13. Essers I, van Tubergen A, Heldmann F, Baraliakos X, Braun J, Kiltz U, Boonen A. Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors. *RMD Open* 2015 Nov 17; 1(1): e000164.
 14. Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? *RMD Open* 2015 Aug 15; 1 (Suppl 1): e000053.
 15. Braun J. Aktuelle Therapie der axialen Spondyloarthritis. *Drug Res (Stuttg)* 2015 Nov; 65 Suppl 1:S8-S10. Epub 2015 Nov 4.
 16. van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. Clinical Responses and Improvements in Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol. *Value Health* 2015 Nov; 18(7): A654. Epub 2015 Oct 20.
 17. Baraliakos X, Coates LC, Braun J. The involvement of the spine in psoriatic arthritis. *Clin Exp Rheumatol*. 2015 Sep-Oct; 33(5 Suppl 93): 31-5. Epub 2015 Oct 15.
 18. Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. *Ann Rheum Dis*. 2015 Oct 13. [Epub ahead of print]
 19. Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. *J Intern Med* 2015 Sep 25. [Epub ahead of print]
 20. Krause D, Gabriel B, Herborn G, Braun J, Rau R. Radiologic damage at baseline predicts patient-related outcomes 18 years after the initiation of methotrexate therapy in patients with severe rheumatoid arthritis. *Clin Exp Rheumatol* 2015 Aug 27. [Epub ahead of print]
 21. Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Van den Bosch F, Logeart I, Wajdula J, Jones H, Marshall L, Bonin R, Pedersen R, Vlahos B, Kotak S, Bukowski JF. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. *Ann Rheum Dis*. 2015 Aug 12. pii: annrheumdis-2015-207596. [Epub ahead of print]

22. Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. *Ann Rheum Dis*. 2015 Aug 6. [Epub ahead of print]
23. Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, Syrbe U, Braun J, Rudwaleit M. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). *Ann Rheum Dis*. 2015 Aug 4. [Epub ahead of print]
24. Tran-Duy A, Nguyen TT, Thijs H, Baraliakos X, Heldmann F, Braun J, Boonen A. Presenteeism is a better predictor of sick leave than BASDAI and BASFI in a cohort of patients with ankylosing spondylitis. *Arthritis Care Res (Hoboken)* 2015 Jul 20. [Epub ahead of print]
25. Buchbender C, Ostendorf B, Ruhlmann V, Heusch P, Miese F, Beiderwellen K, Schneider M, Braun J, Antoch G, Baraliakos X. Hybrid 18F-labeled Fluoride Positron Emission Tomography/Magnetic Resonance (MR) Imaging of the Sacroiliac Joints and the Spine in Patients with Axial Spondyloarthritis: A Pilot Study Exploring the Link of MR Bone Pathologies and Increased Osteoblastic Activity. *J Rheumatol* 2015 Jul 1. [Epub ahead of print]
26. Braun J, Baraliakos X, Regel A, Kiltz U. Assessment of spinal pain. *Best Pract Res Clin Rheumatol*. 2014 Dec; 28(6): 875-87. Epub 2015 May 28.
27. Braun J, Kiltz U, Sarholz M, Heldmann F, Regel A, Baraliakos X. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. *Expert Rev Clin Immunol* 2015 Jun 5:1-12. [Epub ahead of print]
28. Poddubnyy D, Haibel H, Braun J, Rudwaleit M, Sieper J. Clinical course over two years in patients with early non-radiographic axial spondyloarthritis and ankylosing spondylitis without anti-tumor necrosis factor α treatment: Results from the GERman SPondyloarthritis Inception Cohort (GESPIC). *Arthritis Rheumatol* 2015 May 27. [Epub ahead of print]
29. Braun J, Baraliakos X, Kiltz U. Non-radiographic axial spondyloarthritis: a classification or a diagnosis? *Clin Exp Rheumatol*. 2015 Apr 17. [Epub ahead of print]
30. Sieper J, Braun J. Lessons learnt from 15 years of investigator-initiated trials on axial spondyloarthritis. *Z Rheumatol* 2015 Mar; 74(2):125-31
31. Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. *Immunotherapy* 2015 Feb; 7(2): 73-87
32. Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. *Expert Opin Emerg Drugs* 2015 Jan 9:1-14. [Epub ahead of print]
33. Sieper J, Landewé R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP. Effect of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis: Results from a Phase 3 Randomized Trial. *Arthritis Rheumatol* 2014 Dec 2
34. Märker-Hermann E, Kiltz U, Braun J. Treatment of chronic back pain: Current standards. *Internist (Berl)* 2014 Dec; 55(12): 1410-8

35. Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J. Classification and Diagnosis of Axial Spondyloarthritis - What Is the Clinically Relevant Difference? *J Rheumatol* 2014 Nov 15
36. Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. *Ann Rheum Dis* 2014 Nov 11
37. Lorenz HM, Braun J, Krüger K, Schneider M. Implementation and use of biosimilars in the therapy of inflammatory rheumatic diseases : Statement of the German Society of Rheumatology. *Z Rheumatol* 2014 Nov; 73(9):784-6
38. Kiltz U, van der Heijde DM, Boonen A, Braun J. The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. *Clin Exp Rheumatol* 2014 Nov-Dec; 32 Suppl 85(5): 105-108. Epub 2014 Oct 30.
39. Braun J, Kiltz U, Baraliakos X, van der Heijde DM. Optimisation of rheumatology assessments - the actual situation in axial spondyloarthritis including ankylosing spondylitis. *Clin Exp Rheumatol* 2014 Nov-Dec; 32 Suppl 85(5): 96-104. Epub 2014 Oct 30.
40. Pincus T, Braun J, Kavanaugh A, Smolen JS. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care. *Clin Exp Rheumatol*. 2014 Sep-Oct; 32 Suppl 85(5):1. Epub 2014 Oct 30.
41. Heldmann F, Kiltz U, Baraliakos X, Braun J. SAPHO syndrome. *Z Rheumatol* 2014 Oct; 73(8): 729-41
42. Kiltz U, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms : Editorial. *Z Rheumatol*. 2014 Sep; 73 Suppl 2:20-2.
43. Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Böhle E, Böhm H, Böhncke WH, Chenot JF, Heiligenhaus A, Hermann KG, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschläger U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms : 1 Introduction/ preliminary comments. *Z Rheumatol*. 2014 Sep; 73 Suppl 2:23-5.
44. Trampisch US, Krause D, Trampisch HJ, Klaassen-Mielke R, Baraliakos X, Braun J. Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. *Trials*. 2014 Sep 2;15(1):344. [Epub ahead of print]
45. Deodhar A, Reveille J, van den Bosch F, Braun J, Burgos Vargas R, Clegg D, Colbert R, Gensler L, van der Heijde D, van der Horst-Bruinsma I, Inman R, Caplan L, Maksymowych W, Mease P, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman M, Landewé R. The Concept of Axial Spondyloarthritis: SPARTAN and ASAS joint Statement in response to FDA's comments and concerns. *Arthritis Rheumatol* 2014 Aug 25 [Epub ahead of print]
46. Meyer MF, Braun J. Relevance of the current discussion on prioritization for rheumatology. *Z Rheumatol* 2014 Aug 16 [Epub ahead of print]
47. van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C; GO-RAISE investigators. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. *J Rheumatol* 2014 Jun; 41(6):1095-103 Epub 2014 Apr 15.
48. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J,

- Koenig AS, Vlahos B, Alvarez D, Bukowski JF. The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis. *Arthritis Rheumatol* 2014 May 28. [Epub ahead of print]
49. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, MacCarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK; EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis* 2014 Jun 1;73(6):1012-9.
 50. Krause D, Gabriel B, Herborn G, Braun J, Rau R. The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline. *Clin Exp Rheumatol* 2014 Apr 28. [Epub ahead of print]
 51. Braun J, Baraliakos X, Heldmann F, Kiltz U. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. *Expert Opin Investig Drugs* 2014 Mar 22. [Epub ahead of print]
 52. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahn T, Yancopoulos GD, Stahl N, Inman RD. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). *Ann Rheum Dis* 2014 Feb 18 [Epub ahead of print]
 53. Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. *Ann Rheum Dis* 2014 Jan 7 [Epub ahead of print]
 54. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. *Ann Rheum Dis* 2013 Dec 16 [Epub ahead of print].
 55. Braun J, Baraliakos X, Heldmann F, Kiltz U. What is ascertained in the therapy of axial spondyloarthritis? *Internist (Berl)* 2013 Nov 23 [Epub ahead of print].
 56. Kiltz U, Baraliakos X, Braun J, van der Heijde D. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design ? *Clin Exp Rheumatol*. 2013 Jul-Aug; 31(4 Suppl 78):S47-50. Epub 2013 Oct 4.
 57. Baraliakos X, Kiltz U, Heldmann F, Sieper J, Braun J. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. *Clin Exp Rheumatol*. 2013 Jul-Aug; 31(4 Suppl 78):S43-6. Epub 2013 Oct 3.
 58. Song IH, Haibel H, Poddubnyy D, Braun J, Sieper J. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. *Clin Exp Rheumatol* 2013 Jul-Aug; 31(4 Suppl 78):S37-42. Epub 2013 Oct 3.
 59. Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. *Clin Exp Rheumatol* 2013 Jul-Aug; 31(4 Suppl 78):S33-6 Epub 2013 Oct 3.
 60. Pincus T, Braun J, Kavanaugh A, Smolen JS. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision

between patient and rheumatologist. Clin Exp Rheumatol 2013 Jul-Aug; 31(4 Suppl 78):S1-3 Epub 2013 Oct 3.

61. Baraliakos X, Braun J. Response to the eLetter by Maksymowych WP, entitled 'Evidence in Support of the Validity of the TNF Brake Hypothesis'. Ann Rheum Dis 2013 Sep 20 [Epub ahead of print]
62. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachet A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013 Sep 12 pii: S0140-6736(13)61134-4 [Epub ahead of print]
63. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2013 Sep 6 [Epub ahead of print]
64. Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J, Rudwaleit M, Sieper J. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 2013 Aug 16 [Epub ahead of print]
65. Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 2013 Aug 14 [Epub ahead of print].
66. Baraliakos X, Listing J, Haibel H, Sieper J, Braun J. Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy. J Rheumatol 2013 Aug 1 [Epub ahead of print].
67. Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, van der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, de Vlam K, Pappas D, Kiltz U, van Der Heijde D, Braun J. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 2013 Jul 14 [Epub ahead of print].
68. Poddubnyy D, Gaydukova I, Hermann KG, Song IH, Haibel H, Braun J, Sieper J. Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis. J Rheumatol 2013 Jul 1 [Epub ahead of print].
69. Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J. Long-term outcome of patients with active ankylosing spondylitis with etanercept - sustained efficacy and safety after seven years. Arthritis Res Ther 2013 Jun 20; 15(3):R67 [Epub ahead of print].

70. Baraliakos X, Braun J. Perspectives on imaging in axial spondyloarthritis. *Nat Rev Rheumatol* 2013 Jun 18 [Epub ahead of print].
71. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, Wit MD, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JC, Winthrop K, van der Heijde D. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Ann Rheum Dis* 2013 Jun 8 [Epub ahead of print].
72. Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, Wit MD, van der Heijde D. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. *Ann Rheum Dis* 2013 Jun 5 [Epub ahead of print].
73. van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. Improvements in productivity at paid work and within household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of axial spondyloarthritis patients, including patients with ankylosing spondylitis: results of a phase 3 double-blind randomized placebo-controlled study. *Value Health* 2013 May; 16(3): A228-9. Epub 2013 May 3.
74. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis* 2013 May 16. [Epub ahead of print].
75. Haibel H, Heldmann F, Listing J, Kupper H, Braun J, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment of flare patients in active non-radiographic, axial spondyloarthritis. *Arthritis Rheum* 2013 May 17.
76. Machado P, Landewé R, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. *Ann Rheum Dis* 2013 Jun; 72(6):1104-7. Epub 2013 Feb 19.
77. Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou Y, Xu S, Hsu B. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. *Ann Rheum Dis* 2013; May 6 [Epub ahead of print].
78. Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. *Ann Rheum Dis* 2013 May 3 [Epub ahead of print].
79. Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GERMAN SPondyloarthritis Inception Cohort (GESPIC). *Ann Rheum Dis* 2013 Apr 26 [Epub ahead of print].

80. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. *Ann Rheum Dis* 2013 Apr 26. [Epub ahead of print]
81. Braun A, Gnann H, Saracbası E, Grifka J, Kiltz U, Letschert K, Braun J. Optimising the identification of patients with axial spondyloarthritis in primary care – the case for a two-step strategy combining the most relevant clinical items with HLA B27. *Rheumatology* 2013 April 4 [Epub ahead of print].
82. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, van Riel PL, Weisman MH, Winthrop KL. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis* 2013 Apr; 72 Suppl 2:ii2-ii34.
83. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. *Ann Rheum Dis* 2013 Mar 16 [Epub ahead of print].
84. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. *Ann Rheum Dis* 2013 Jan 29 [Epub ahead of print].
85. Häusler U, Guminski B, Helmchen U, Kisters K, Heinz C, Braun J. Tubulointerstitial nephritis with uveitis (TINU) syndrome: A relatively rare rheumatological differential diagnosis with unexplained uveitis. *Z Rheumatol* 2013 Jan 23 [Epub ahead of print]
86. Kiltz U, Sieper J, Braun J. ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis: Evaluation of the 2010 update in the German-speaking area. *Z Rheumatol* 2013 Jan 20 [Epub ahead of print].
87. Kiltz U, Sieper J, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis: evaluation of the 2010 update in the German-speaking area. *Z Rheumatol* 2012 Dec 7 [Epub ahead of print].
88. Braun J, Sieper J, Zink A. Republished: The risks of smoking in patients with spondyloarthritides. *Postgrad Med J* 2012 Nov; 88(1045): 617-8.
89. Braun J, Sieper J. Preface. *Rheum Dis Clin North Am* 2012 Aug; 38(3): xvii-xxi. Epub 2012 Sep 1.
90. Sieper J, Braun J. How Important is Early Therapy in Axial Spondyloarthritis ? *Rheum Dis Clin North Am* 2012 Aug; 38(3): 635-42. Epub 2012 Sep 13.
91. Braun J, Sieper J. Preface. *Rheum Dis Clin North Am* 2012 Aug; 38(3): xvii-xxi. Epub 2012 Sep 1.
92. Baraliakos X, Hermann KG, Braun J. Imaging in axial spondyloarthritis: diagnostic problems and pitfalls. *Rheum Dis Clin North Am* 2012 Aug; 38(3): 513-22. Epub 2012 Sep 25.
93. Burgos-Vargas R, Braun J. Inflammatory back pain. *Rheum Dis Clin North Am* 2012 Aug; 38(3): 487-99 Epub 2012 Sep 14.
94. Braun J, Sieper J. Classification, diagnosis, and referral of patients with axial spondyloarthritis. *Rheum Dis Clin North Am* 2012 Aug; 38(3): 477-85. Epub 2012 Sep 15.

95. Braun J, Smolen JS. Gout: thoughts about a treat-to-target programme. *Clin Exp Rheumatol* 2012 Oct 16 [Epub ahead of print].
96. Braun J. Axial spondyloarthritis: thoughts about nomenclature and treatment targets. *Clin Exp Rheumatol* 2012 Oct 16. [Epub ahead of print]
97. Turchetti G, Smolen JS, Kavanaugh A, Braun J, Pincus T, Bombardieri S. Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction. *Clin Exp Rheumatol* 2012 Jul-Aug; 30(4 Suppl 73):S1 [Epub 2012 Nov 20].
98. van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). *Rheumatology (Oxford)* 2012 Sep 28 [Epub ahead of print].
99. Kiltz U, Baraliakos X, Braun J. Spondyloarthritis - the novel concept. *Dtsch Med Wochenschr* 2012 Sep; 137(36): 1745-7 [Epub 2012 Aug 29].
100. Baraliakos X, Braun J. A 34-year-old patient with non-radiographic axial spondyloarthritis and acute back pain. *Dtsch Med Wochenschr* 2012 Sep; 137(36): 1743-4. [Epub 2012 Aug 29].
101. van Werde M, Ruetten S, Baraliakos X, Godolias G, Braun J. Differential diagnosis of back pain in patients with ankylosing spondylitis: instable cervical spine fracture. *Dtsch Med Wochenschr* 2012 Sep; 137(36):1740-2 [Epub 2012 Aug 29].
102. Sarholz M, Vorgerd M, Braun J. Camptocormia in the differential diagnosis of hyperkyphosis and ankylosing spondylitis. *Dtsch Med Wochenschr* 2012 Sep; 137(36): 1736-9 [Epub 2012 Aug 29].
103. Braun J. Rheumatology: present and future. *Dtsch Med Wochenschr* 2012 Sep; 137(36): 1735 [Epub 2012 Aug 29].
104. Krüger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U. German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis: Adapted EULAR recommendations and updated treatment algorithm. *Z Rheumatol* 2012 Sep; 71(7): 592-603.
105. Braun J, Schneider M, Genth E. Rheumatology - current and future treatment of inflammatory and non-inflammatory musculoskeletal diseases in Germany: An assessment by the board of the German Society for Rheumatology. *Z Rheumatol* 2012 Sep; 71(7): 544-9.
106. Machado P, Landewé RB, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. *Ann Rheum Dis* 2012 Aug 21 [Epub ahead of print].
107. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Haug-Rost I, Braun J, Sieper J. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. *Ann Rheum Dis* 2012 Aug 11 [Epub ahead of print].
108. Braun J, Schneider M, Genth E. Quo vadis rheumatology: Closed conference of the executive board and advisory committee of the German Society for Rheumatology 2011. *Z Rheumatol* 2012 Aug; 71(6): 456-8.

109. Baraliakos X, Braun J. Biologic Therapies for Spondyloarthritis: What is new ? *Curr Rheumatol Rep* 2012 Aug 2 [Epub ahead of print].
110. van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS. Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial. *Rheumatology (Oxford)* 2012 July 6 [Epub ahead of print].
111. van der Heijde D, Deodhar A, Inman RD, Braun J, Hsu B, Mack M. Comparison of three methods for calculating the bath ankylosing spondylitis metrology index in the GO-RAISE study. *Arthritis Care Res (Hoboken)* 2012 Jun 27 [Epub ahead of print].
112. Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. *Rheumatology (Oxford)* 2012 May 30 [Epub ahead of print].
113. Hermann KG, Baraliakos X, van der Heijde DM, Jurik AG, Landewé R, Marzo-Ortega H, Ostergaard M, Rudwaleit M, Sieper J, Braun J; on behalf of the Assessment in SpondyloArthritis international Society (ASAS). Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. *Ann Rheum Dis* 2012 May 14 [Epub ahead of print].
114. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Floercke M, Bollow M, Braun J. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. *Ann Rheum Dis* 2012 Apr 20 [Epub ahead of print].
115. van den Berg R, Baraliakos X, Braun J, van der Heijde D. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Rheumatology (Oxford)* 2012 Apr 17 [Epub ahead of print].
116. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Flörecke M, Bollow M, Braun J. Patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis in several aspects. *Arthritis Care Res (Hoboken)* 2012 Apr 13 [Epub ahead of print].
117. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Ann Rheum Dis*. 2012 Apr; 71 Suppl 2:i2-i45.
118. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Ann Rheum Dis* 2012 Mar 29 [Epub ahead of print].
119. Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives ? *Curr Opin Rheumatol* 2012 May; 24(3): 252-60.
120. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR

management recommendations of ankylosing spondylitis. *Rheumatology* (Oxford) 2012 Mar 16 [Epub ahead of print].

121. Fendler C, Saracbası E, Dybowski F, Heldmann F, Braun J. Practical problems by implementation of vaccination recommendations. *Z Rheumatol* 2012 Feb; 71(2): 147-55
122. Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, Koenig AS. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. *J Rheumatol* 2012 Feb 15 [Epub ahead of print]
123. Braun J, Sieper J, Zink A. The risks of smoking in patients with spondyloarthritides. *Ann Rheum Dis* 2012 Jun; 71(6):791-2 [Epub 2012 Feb 13].
124. Dougados M, Braun J, Vargas RB, Gossec L, Maksymowych W, Sieper J, van der Heijde D. ASAS recommendations for variables to be collected in clinical trials/ epidemiological studies of spondyloarthritis. *Ann Rheum Dis* 2012 Jun; 71(6): 1103-4. [Epub 2012 Jan 30].
125. Baraliakos X, Braun J. MRI examinations for axial and peripheral spondyloarthritis. *Z Rheumatol* 2012 Jan; 71(1):27-37.
126. Appel H, Braun J. Synovitis in spondyloarthritides. *Open Rheumatol J* 2011; 5: 123-6. [Epub 2011 Dec 30].
127. Baraliakos X, Braun J. Spondyloarthritides. *Best Pract Res Clin Rheumatol* 2011 Dec; 25(6): 825-42.
128. Braun J, Baraliakos X. Spondyloarthropathies: The disease process in axial SpA: what can biomarkers tell us ? *Nat Rev Rheumatol* 2011 Dec 23; 8(1):8-10
129. Braun J, Krueger K, Genth E. Stellungnahme zum IQWiG. *Z Rheumatol* 2011 Dec; 70(10): 882-3.
130. Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, Baratelle A, Xu S, Xu W, Hsu B. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study. *Ann Rheum Dis* 2012 Jun; 71(6): 878-84. Epub 2011 Nov 29.
131. Poddubnyy D, Haibel H, Listing J, Maerker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Baseline radiographic damage, elevated acute phase reactants and cigarette smoking status predict radiographic progression in the spine in early axial spondyloarthritis. *Arthritis Rheum* 2012 May; 64(5):1388-982011 [Epub 2011 Nov 29].
132. Wagner C, Visvanathan S, Braun J, van der Heijde D, Deodhar A, Hsu B, Mack M, Elashoff M, Inman RD. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. *Ann Rheum Dis* 2012 May; 71(5):674-80 [Epub 2011 Oct 28].
133. Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. *Ann Rheum Dis* 2012 May; 71(5): 661-7 [Epub 2011 Oct 19].
134. Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I. NSAID-intake according to the ASAS score in clinical trials evaluating TNF blockers: The example of etanercept in advanced ankylosing spondylitis. *Arthritis Care Res (Hoboken)* 2012 Feb; 64(2):290-4 [Epub 2011 Oct 17].
135. Dybowski F, Moos F, Saracbası-Zender E, Heldmann F, Braun J. Generalized osteoarthritis in a young adult with type II collagenopathy. *Dtsch Med Wochenschr* 2011 Oct; 136(42): 2147-51 [Epub 2011 Oct 11].

136. Lakomek HJ, Robbers J, Koshedub R, Krause A, Braun J. How to finance and increase the appeal of rheumatology training : View of the Association of Rheumatology Clinics in Germany (VRA) on challenges and successful strategies. *Z Rheumatol* 2011 Oct; 70(8): 712-8.
137. Braun J, Wollenhaupt J, Genth E. Further education: a core responsibility of the German Society for Rheumatology and the Rheuma Academy. *Z Rheumatol* 2011 Oct; 70(8): 701-11.
138. Fendler C, Baraliakos X, Braun J. Glucocorticoid treatment in spondyloarthritis. *Clin Exp Rheumatol* 2011 Sep-Oct; 29(5 Suppl 68):S139-42 [Epub 2011 Oct 22].
139. Krause D, Rau R, Braun J. Glucocorticoid treatment in early rheumatoid arthritis. *Clin Exp Rheumatol*. 2011 Sep-Oct; 29(5 Suppl 68):S121-5 [Epub 2011 Oct 22].
140. Pincus T, Bijlsma JW, Braun J, Buttgereit F, Cutolo M. Low-dose glucocorticoids in rheumatic diseases: introduction. *Clin Exp Rheumatol* 2011 Sep-Oct; 29(5 Suppl 68): S2-4 [Epub 2011 Oct 21].
141. van der Heijde D, Machado P, Braun J, Hermann KG, Baraliakos X, Hsu B, Baker D, Landewé R. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012 Mar; 71(3):369-73 [Epub 2011 Oct 6].
142. Baraliakos X, Listing J, Buschmann J, von der Recke A, Braun J. A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years. *Arthritis Rheum* 2012 Apr; 64(4):1127-33 [Epub 2011 Oct].
143. Heberlein I, Demary W, Braun J, Buttgereit F, Dreher R, Kuhn C, Lange U, Pollähne W, Zink A, Zeidler H, Häntzschel H, Raspe H. Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study). *Z Rheumatol* 2011 Sep 30 [Epub ahead of print].
144. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, Fitzgerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis* 2012 Jan; 71(1):4-12 [Epub 2011 Sep 9].
145. Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J. The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. *Clin Exp Rheumatol* 2011 Jul-Aug; 29(4):672-80 [Epub 2011 Aug 31].
146. Baraliakos X, van der Heijde D, Braun J, Landewé RB. OMERACT Magnetic Resonance Imaging Initiative on Structural and Inflammatory Lesions in Ankylosing Spondylitis - Report of a Special Interest Group at OMERACT 10 on Sacroiliac Joint and Spine Lesions. *J Rheumatol* 2011 Sep; 38(9):2051-4.
147. Poddubnyy DA, Märker-Hermann E, Kaluza-Schilling W, Zeidler H, Braun J, Listing J, Sieper J, Rudwaleit M. Relation of HLA-B27, Tumor Necrosis Factor- α Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis - A

Comprehensive Genotype-Phenotype Analysis from an Observational Cohort. *J Rheumatol* 2011 Sep 1 [Epub ahead of print].

148. Lakomek HJ, Braun J, Gromnica-Ihle E, Fiehn C, Claus S, Specker C, Jung J, Krause A, Lorenz HM, Robbers J. Amendment of the structural quality for inpatient rheumatology: A forward-looking concept. *Z Rheumatol* 2011 Aug 21 [Epub ahead of print].
149. Braun A, Saracbası E, Grifka J, Schnitker J, Braun J. Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? *Ann Rheum Dis* 2011 Oct; 70(10): 1782-7 [Epub 2011 Aug 5].
150. Machado P, Landewé R, Braun J, Hermann KG, Baraliakos X, Baker D, Hsu B, van der Heijde D. A stratified model for health outcomes in ankylosing spondylitis. *Ann Rheum Dis* 2011 Jul 25 [Epub ahead of print].
151. Heberlein I, Demary W, Bloching H, Braun J, Buttgereit F, Dreher R, Kuhn C, Lange U, Zink A, Zeidler H, Häntzschel H, Raspe H. Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines : Results of a survey of patients, primary care physicians and rheumatologists. *Z Rheumatol* 2011 Jul 14 [Epub ahead of print].
152. Kiltz U, Sieper J, Braun J. Development of morbidity and mortality in patients with spondyloarthritis. *Z Rheumatol* 2011 Jul 8 [Epub ahead of print].
153. Baraliakos X, Listing J, von der Recke A, Braun J. The Natural Course of Radiographic Progression in Ankylosing Spondylitis: Differences Between Genders and Appearance of Characteristic Radiographic Features. *Curr Rheumatol Rep.* 2011 Jun 25 [Epub ahead of print].
154. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years - early clinical response predicts long-term outcome. *Rheumatology (Oxford)* 2011 Jun 14 [Epub ahead of print].
155. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. *Ann Rheum Dis* 2011 May 27 [Epub ahead of print].
156. Braun J, Rudwaleit M, Sieper J. Spondyloarthritis. *Internist.* 2011 May 19
157. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, Rudwaleit M, Braun J; for the Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Ann Rheum Dis* 2011 Jun; 70(6): 905-908.
158. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman R, Jongkees M, Khan M, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych W, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2011 Jun; 70(6):896-904.
159. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiß A, Braun J, Sieper J. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. *Ann Rheum Dis* 2011 Mar 17 [Epub ahead of print].

160. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Predicting the outcome of ankylosing spondylitis therapy. *Ann Rheum Dis* 2011 Mar 14 [Epub ahead of print].
161. Braun J, Baraliakos X. Imaging of axial spondyloarthritis including ankylosing spondylitis. *Ann Rheum Dis* 2011 Mar; 70 Suppl 1:i97-i103.
162. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Doerner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. *Ann Rheum Dis* 2011 Mar; 70 Suppl 1:i2-i36
163. Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, Logeart I. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). *Ann Rheum Dis* 2011 Feb 13 [Epub ahead of print].
164. Braun J. Arthritis of the atlanto-axial joint with inflammatory neck pain as a primary manifestation of seronegative rheumatoid arthritis. *Dtsch Med Wochenschr* 2011 Feb; 136(7): 331-332 Epub 2011 Feb 7.
165. Swoboda B, Villiger P, Braun J. Elective rheumatology surgery from the perspective of the rheumatoid orthopaedist and the rheumatologist. *Z Rheumatol* 2011 Jan; 70(1): 7-8.
166. Heldmann F, Dybowski F, Baraliakos X, Braun J. Perioperative use of biologicals in rheumatoid arthritis. *Z Rheumatol*. 2011 Jan; 70(1):14-20.
167. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B. Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: A randomized, double-blind study (ASCEND Trial). *Arthritis Rheum* 2011 Jan 10 [Epub ahead of print] 2011 Jun; 63(6): 1543-51.
168. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). *Ann Rheum Dis* 2010 Dec 27 [Epub ahead of print].
169. Kiltz U, van der Heijde D, Cieza A, Boonen A, Stucki G, Ustün B, Braun J. Developing and validating an index for measuring health in patients with ankylosing spondylitis. *Rheumatology (Oxford)* 2010 Dec 13 [Epub ahead of print].
170. Kiltz U, Braun J. Use of methotrexate in patients with sarcoidosis. *Clin Exp Rheumatol* 2010 Sep-Oct; 28(5 Suppl 61):S183-5 [Epub 2010 Oct 28].
171. Fendler C, Braun J. Use of methotrexate in inflammatory myopathies. *Clin Exp Rheumatol* 2010 Sep-Oct; 28(5 Suppl 61):S164-7 [Epub 2010 Oct 28].
172. Heldmann F, Braun J. Perioperative use of methotrexate. *Clin Exp Rheumatol* 2010 Sep-Oct; 28(5 Suppl 61):S110-3 [Epub 2010 Oct 28].
173. Braun J. Optimal administration and dosage of methotrexate. *Clin Exp Rheumatol* 2010 Sep-Oct; 28(5 Suppl 61):S46-51 [Epub 2010 Oct 28].
174. Pincus T, Cronstein B, Braun J. Methotrexate - the anchor drug - an introduction. *Clin Exp Rheumatol* 2010 Sep-Oct; 28(5 Suppl 61):S1-2 [Epub 2010 Oct 28].
175. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D; for the Assessment of SpondyloArthritis International Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis*. 2010 Nov 10 [Epub ahead of print].

176. Braun J, Genth E; für den Vorstand der DGRh. Lest we forget : Statement by the German Rheumatology Society (DGRh) on the national socialist crimes against Jewish colleagues. *Z Rheumatol*. 2010 Oct 14 [Epub ahead of print].
177. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. *Ann Rheum Dis* 2010 Sep 9 [Epub ahead of print].
178. Haeusler U, Dybowski F, Wittkaemper TA, Kisters K, Godolias G, Braun J. Arthritis of the atlanto-axial joint with inflammatory neck pain as a primary manifestation of seronegative rheumatoid arthritis. *Dtsch Med Wochenschr* 2010 Sep; 135(36):1729-1732. [Epub 2010 Sep 1].
179. Heldmann F, Dybowski F, Saracbas-Zender E, Fendler C, Braun J. Update on Biologic Therapy in the Management of Axial Spondyloarthritis. *Curr Rheumatol Rep* 2010 Jul 28 [Epub ahead of print].
180. Braun J, Inman R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. *Ann Rheum Dis* 2010 Jul; 69(7): 1264-8.
181. Suppiah R, Doyle A, Rai R, Dalbeth N, Lobo M, Braun J, McQueen FM. Quantifying Bone Marrow Edema in the Rheumatoid Cervical Spine Using Magnetic Resonance Imaging. *J Rheumatol* 2010 Jun 15 [Epub ahead of print].
182. Dougados M, Combe B, Braun J, Landewé R, Sibilia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. *Ann Rheum Dis* 2010 May 28. [Epub ahead of print]
183. Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van der Heijde D. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial. *Arthritis Care Res (Hoboken)* 2010 Apr 21 [Epub ahead of print].
184. Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D. Both, structural damage and inflammation of the spine, contribute to impairment of spinal mobility in patients with ankylosing spondylitis. *Ann Rheum Dis* 2010 May 24 [Epub ahead of print].
185. Poddubnyy D, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. *Ann Rheum Dis* 2010 May 24 [Epub ahead of print]
186. Braun J, Sieper J. Spondyloarthritis. *Z Rheumatol* 2010 May 21 [Epub ahead of print].
187. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Different response to rituximab in tumor necrosis factor blocker-naïve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. *Arthritis Rheum* 2010 May; 62(5):1290-7.
188. Müller-Ladner U, Rockwitz K, Brandt-Jürgens J, Haux R, Kästner P, Braun J, Demary W, Guimbal-Schmolck C, Pichlmeier U, Brandt A; for the MC-MTX 10/RH Study Group. Tolerability and Patient/Physician Satisfaction with Subcutaneously Administered Methotrexate Provided in Two Formulations of Different Drug Concentrations in Patients with Rheumatoid Arthritis. *Open Rheumatol J* 2010 Mar 18; 4:15-22.

189. Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. *Rheumatology (Oxford)* 2010 May 6 [Epub ahead of print].
190. Braun J, Pfeilschifter J. Osteoporosis diagnosis and therapy according to the 2010 guidelines. *Z Rheumatol* 2010 Apr 18 [Epub ahead of print]
191. Baraliakos X, Braun J. Anti-TNF-alpha therapy with infliximab in spondyloarthritis. *Expert Rev Clin Immunol* 2010 Jan; 6(1): 9-19.
192. Kalden JR, Braun J. A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases. *Clin Exp Rheumatol* 2009 Jul-Aug; 27(4 Suppl 55): S168-70.
193. Braun J, Kalden JR. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009 Jul-Aug; 27(4 Suppl 55): S164-7
194. Braun J, Sieper J. Treatment of rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009 Jul-Aug; 27(4 Suppl 55):S146-7.
195. Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009 Jul-Aug; 27(4 Suppl 55):S127-30.
196. Fendler C, Braun J. Clinical measures in rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009 Jul-Aug; 27(4 Suppl 55): S80-2.
197. Braun J, Sieper J. Classification criteria for rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009 Jul-Aug; 27(4 Suppl 55): S68-73.
198. Braun J, Sieper J, Pincus T. A systematic comparison between rheumatoid arthritis and ankylosing spondylitis: an introduction. *Clin Exp Rheumatol* 2009 Jul-Aug; 27(4 Suppl 55):S1-2.
199. Bochkova AG, Levshakova AV, Bunchuk NV, Braun J. Spinal inflammation lesions as detected by magnetic resonance imaging in patients with early ankylosing spondylitis are more often observed in posterior structures of the spine. *Rheumatology (Oxford)* 2010 Jan 18 [Epub ahead of print].
200. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnahan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. *Ann Rheum Dis* 10 Jan; 69 Suppl 1:i2-29.
201. Braun J. Ankylosing spondylitis. *MMW Fortschr Med* 2009 Nov 19;151(47):79-83, quiz 84.
202. Baraliakos X, Braun J. Hip involvement in ankylosing spondylitis: what is the verdict ? *Rheumatology (Oxford)* 2009 Sep 15 [Epub ahead of print].
203. Braun J. Therapy of spondyloarthritis. *Adv Exp Med Biol* 2009;649:133-47.
204. Franck H; Kommission Osteologie der Deutschen Gesellschaft für Rheumatologie, Braun J, Buttgereit F, Demary W, Hein G, Kekow J, Schett G, Kern PM. Bone densitometry in inflammatory rheumatic diseases: Characteristics of the measurement site and disease-specific factors. *Z Rheumatol* 2009 Aug 29. [Epub ahead of print]
205. Rudwaleit M, Braun J, Sieper J. ASAS classification criteria for axial spondyloarthritis. *Z Rheumatol* 2009 Aug 14 [Epub ahead of print].
206. Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R, Vlam KD, Burmester GR, Van den Bosch F, Xu S, Visvanathan S, Rahman MU. Improvement in

- hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. *Arthritis Rheum* 2009 Jul 30; 61(8):1032-1036 [Epub ahead of print].
207. Kiltz U, Rudwaleit M, Sieper J, Braun J. New aspects in the area of spondyloarthritis: Report on the 6(th) International Congress on Spondyloarthropathies. *Z Rheumatol* 2009 Jun 26 [Epub ahead of print].
 208. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: Addition of the thoracic spine improves sensitivity to change. *Arthritis Rheum* 2009 May 28;61(6):764-771 [Epub ahead of print].
 209. Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. *Curr Opin Rheumatol* 2009 May 20 [Epub ahead of print].
 210. Rudwaleit M, Jurik AG, Hermann KG, Landewé R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J. Defining active sacroiliitis on Magnetic Resonance Imaging (MRI) for classification of axial spondyloarthritis - a consensual approach by the ASAS/OMERACT MRI Group. *Ann Rheum Dis* 2009 May 18 [Epub ahead of print].
 211. Braun J, Sieper J. Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe. *Z Rheumatol* 2009 May 17 [Epub ahead of print].
 212. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewé R, Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis* 2009 Feb; 68 Suppl 2:ii1-44.
 213. Braun J, Rau R. An update on methotrexate. *Curr Opin Rheumatol* 2009 May; 21(3): 216-23.
 214. Baraliakos X, Listing J, von der Recke A, Braun J. The Natural Course of Radiographic Progression in Ankylosing Spondylitis - Evidence for Major Individual Variations in a Large Proportion of Patients. *J Rheumatol* 2009 Mar 30 [Epub ahead of print].
 215. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part I): Classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis* 2009 Mar 17. [Epub ahead of print]
 216. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection. *Ann Rheum Dis* 2009 Mar 17. [Epub ahead of print]
 217. Boonen A, Braun J, van der Horst-Bruinsma IE, Huang F, Maksymowych WP, Kostanjsek N Dr, Cieza A, Stucki G, van der Heijde DM. The ASAS/WHO ICF Core Sets for Ankylosing Spondylitis: how to classify the impact of AS on functioning and health. *Ann Rheum Dis* 2009 Mar 11. [Epub ahead of print]
 218. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. The early disease stage in axial spondylarthritis: Results from the

- German spondyloarthritis inception cohort. *Arthritis Rheum*. 2009 Feb 26;60(3):717-727. [Epub ahead of print]
219. Kiltz U, Feldtkeller E, Braun J. German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Z Rheumatol*. 2009 Feb 14. [Epub ahead of print]
 220. Landewé RB, Günther K, Lukas C, Braun J, Combe B, Conaghan PG, Dreinhöfer K, Fritschy D, Getty J, van der Heide HJ, Kvien TK, Machold K, Mihai C, Mosconi M, Nellissen R, Pascual E, Pavelka K, Pilecky M, Puhl W, Punzi L, Rütter W, San-Julian M, Tudisco C, Westhovens R, Witso E, van der Heijde DM. EULAR/EFORT Recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. *Ann Rheum Dis* 2009 Jan 15. [Epub ahead of print]
 221. Braun J, Sieper J. Ankylosing spondylitis: Target treatment criteria. *Z Rheumatol* 2009 Jan 16 [Epub ahead of print]
 222. Zochling J, Braun J. Mortality in ankylosing spondylitis. *Clin Exp Rheumatol* 2008 Sep-Oct; 26(5 Suppl 5): 80-4
 223. Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Ann Rheum Dis* 2008 Dec; 67 Suppl 3:iii2-25
 224. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R. The ASDAS is a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann Rheum Dis* 2008 Dec 5. [Epub ahead of print]
 225. Kiltz U, Feldtkeller E, Braun J. Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Z Rheumatol* 2008 Dec; 67(8):694-702
 226. Inman RD, Davis JC Jr, Heijde DV, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum* 2008 Oct 30; 58(11): 3402-3412. [Epub ahead of print]
 227. Kiltz U, van der Heijde D, Mielants H, Feldtkeller E, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis - the patient version. *Ann Rheum Dis* 2008 Oct 17 [Epub ahead of print]
 228. Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy - three examples. *J Rheumatol* 2008 Oct; 35 (10): 2074-5
 229. van der Heijde D, Landewé R, Baraliakos X, Houben H, Tubergen AV, Williamson P, Xu W, Baker D, Goldstein N, Braun J; the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. *Arthritis Rheum* 2008 Sep 29; 58(10):3063-3070. [Epub ahead of print]
 230. Braun J, Sieper J. What is the most important outcome in ankylosing spondylitis ? *Rheumatology* 2008 Sept 16 ePub

231. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. *Arthritis Res Ther*. 2008 Sep 1;10(5):R104. [Epub ahead of print]
232. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D; The Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. *Arthritis Rheum*. 2008 Aug 29;59(9):1270-1278. [Epub ahead of print]
233. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis* 2008 Jul 14. [Epub ahead of print]
234. Neidhart M, Baraliakos X, Seemayer C, Zelder C, Gay RE, Michel BA, Boehm H, Gay S, Braun J. Expression of cathepsin K and MMP-1 indicate persistent osteodestructive activity in longstanding ankylosing spondylitis. *Ann Rheum Dis* 2008 Aug 4. [Epub ahead of print]
235. Cieza A, Hilfiker R, Boonen A, van der Heijde D, Braun J, Stucki G. Towards an ICF-based clinical measure of functioning in people with ankylosing spondylitis: A methodological exploration. *Disabil Rehabil*. 2008 Jun 12;1-10. [Epub ahead of print]
236. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, Braun J, Sieper J. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis Rheum* 2008 Jun 24; 58(7):1981-1991 [Epub ahead of print]
237. Braun J. The clinical efficacy and safety of subcutaneous administration of methotrexate in patients with active rheumatoid arthritis. Reply. *Arthritis Rheum* 2008 Jun 24; 58(7): 2209-2210 [Epub ahead of print]
238. Dybowski F, Sepp N, Bergerhausen HJ, Braun J. Successful use of anakinra to treat refractory Schnitzler's syndrome. *Clin Exp Rheumatol* 2008 Mar-Apr; 26(2): 354-7
239. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. *Ann Rheum Dis* 2008 May 21. [Epub ahead of print]
240. Kiltz U, Zochling J, Schmidt WE, Braun J. Use of NSAIDs and infection with *Helicobacter pylori* - what does the rheumatologist need to know ? *Rheumatology (Oxford)* 2008 May 13. [Epub ahead of print]
241. Zochling J, Sieper J, van der Heijde D, Braun J. Development of a Core Set of Domains for Data Collection in Cohorts of Patients with Ankylosing Spondylitis Receiving Anti-Tumor Necrosis Factor- α Therapy. *J Rheumatol* 2008 May 1 [Epub ahead of print]
242. Dybowski F, Neuen-Jacob E, Braun J. Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring. *Ann Rheum Dis* 2008 Apr; 67(4): 572-4
243. Braun J. Canadian recommendations for the management of spondyloarthritis address many different levels of patient care. *Nat Clin Pract Rheumatol* 2008 Mar 11 [Epub ahead of print]

244. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes. *Arthritis Rheum* 2008 Feb 29; 58(3): 649-656 [Epub ahead of print]
245. Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, Rudwaleit M. New Onset of Crohn's Disease During Treatment of Active Ankylosing Spondylitis with Etanercept. *J Rheumatol* 2008 Jan 15 [Epub ahead of print]
246. Kobelt G, Sobocki P, Mulero J, Gratacos J, Collantes-Estevez E, Braun J. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. *Scand J Rheumatol* 2008 Jan-Feb; 37(1): 62-71
247. Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, von Hinüber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A; MC-MTX.6/ RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. *Arthritis Rheum* 2007 Dec 28; 58(1):73-81 [Epub ahead of print]
248. Gossec L, Dougados M, Phillips C, Hammoudeh M, de Vlam K, Pavelka K, Pham T, Braun J, Sieper J, Olivieri I, van der Heijde D, Collantes E, Stone MA, Kvien TK. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of Ankylosing Spondylitis: results of a study among 1.507 rheumatologists. *Ann Rheum Dis* 2007 Nov 29 [Epub ahead of print]
249. van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, Davis JC Jr, Wong RL, Kupper H, Collantes E. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. *Ann Rheum Dis* 2007 Dec 4 [Epub ahead of print]
250. Zochling J, Braun J. Quality indicators, guidelines and outcome measures in ankylosing spondylitis. *Clin Exp Rheumatol* 2007 Nov-Dec; 25(6 Suppl 47): 147-52.
251. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. Magnetic Resonance Imaging (MRI) in predicting a major clinical response to anti-TNF-treatment in ankylosing spondylitis. *Ann Rheum Dis* 2007 Nov 15; [Epub ahead of print]
252. Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji W. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. *Ann Rheum Dis* 2007 Oct 29; [Epub ahead of print]
253. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Soerensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of anti-TNF- α therapy with infliximab in patients with ankylosing spondylitis over 5 years - evidence for different types of response. *Ann Rheum Dis* 2007 Oct 29; [Epub ahead of print]
254. Han C, Smolen J, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, Zhao N, Rahman MU, Baker D, Bala M. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. *Arthritis Res Ther* 2007 Oct 8; 9(5): R103 [Epub ahead of print]
255. Rehart S, Kerschbaumer F, Braun J, Sieper J. Modern treatment of ankylosing spondylitis. *Orthopaede* 2007 Sep 30; [Epub ahead of print]
256. Braun J, Zochling J, Grill E, Liman W, Stucki G. International classification of functioning, disability and health and its significance for rheumatology. *Z Rheumatol* 2007 Aug 19; [Epub ahead of print]

257. Zochling J, Braun J. Assessments in ankylosing spondylitis. *Best Pract Res Clin Rheumatol* 2007 Aug; 21(4):699-712.
258. Visvanathan S, Wagner CL, Marini JC, van der Heijde D, Baker D, Gathany T, Han J, Braun J. Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. *Ann Rheum Dis* 2007 Jul 20; [Epub ahead of print]
259. Zochling J, Grill E, Alten R, Ernst J, Stucki G, Braun J. Identification of relevant functional issues for the care of patients with acute arthritis by health professionals, using the ICF framework and a multi-disciplinary focus group approach. *Clin Exp Rheumatol* 2007 May-Jun; 25(3):354-60
260. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- α antibody infliximab. *Rheumatology (Oxford)* 2007 Jul 10; [Epub ahead of print]
261. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewe RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van der Heijde D. International Spondyloarthritis Interobserver Reliability Exercise - The INSPIRE Study: II. Assessment of Peripheral Joints, Enthesitis, and Dactylitis. *J Rheumatol* 2007 Jul 15; [Epub ahead of print]
262. Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewe RB, Braun J, Davis JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, Maksymowych WP. International Spondyloarthritis Interobserver Reliability Exercise - The INSPIRE Study: I. Assessment of Spinal Measures. *J Rheumatol* 2007 Jul 1; [Epub ahead of print]
263. Meyer MF, Schmidt O, Hellmich B, Schatz H, Klein HH, Braun J. Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations. *Rheumatol Int* 2007 Jun 29; [Epub ahead of print]
264. Kobelt G, Sobocki P, Sieper J, Braun J. Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. *Int J Technol Assess Health Care*. 2007 Summer; 23(3): 368-75
265. Zochling J, Baraliakos X, Hermann KG, Braun J. Magnetic resonance imaging in ankylosing spondylitis. *Curr Opin Rheumatol* 2007 Jul; 19(4):346-52
266. Grill E, Zochling J, Stucki G, Mittrach R, Scheuringer M, Liman W, Kostanjsek N, Braun J. International Classification of Functioning, Disability and Health (ICF) Core Set for patients with acute arthritis. *Clin Exp Rheumatol* 2007 Mar-Apr; 25(2):252-8
267. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J. Consensus on a core set of domains for psoriatic arthritis. *J Rheumatol* 2007 May; 34(5):1167-70
268. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. *Arthritis Rheum* 2007 May 15; 57(4):639-47

269. Braun J, Sieper J. Ankylosing spondylitis. *The Lancet* 2007; 369:1379-1390
270. Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. *Expert Opin Pharmacother* 2007 Apr; 8(6):831-8
271. Kiltz U, Brandt J, Zochling J, Braun J. Rheumatic manifestations of lymphoproliferative disorders. *Clin Exp Rheumatol* 2007 Jan-Feb; 25(1):35-9
272. van der Heijde D, Landewe R, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Lukas C, Jurik AG, Boers M, Baraliakos X, Braun J. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? *J Rheumatol* 2007 Apr; 34(4): 871-3
273. Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Jurik AG, Baraliakos X. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment *J Rheumatol* 2007 Apr;34(4): 862-70
274. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. *Rheumatology (Oxford)* 2007 Mar 27; [Epub ahead of print]
275. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J. Progression of radiographic damage in patients with ankylosing spondylitis - Defining the central role of syndesmophytes. *Ann Rheum Dis* 2007 Feb 28; [Epub ahead of print]
276. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sorensen H, Zeidler H, Visvanathan S, Sieper J, Braun J. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. *J Rheumatol* 2007 Feb 1; [Epub ahead of print]
277. Braun J, Zochling J, Marker-Hermann E, Stucki G, Bohm H, Rudwaleit M, Zeidler H, Sieper J. Recommendations for the management of ankylosing spodylitis after ASAS/ EULAR: evaluation in the German language area. *Z Rheumatol* 2006 Dec; 65(8):728-742
278. Althoff CE, Hermann KG, Braun J, Sieper J. Ankylosing spondylitis - current state of imaging including scoring methods. *Z Rheumatol* 2006 Dec; 65(8): 688-699
279. Zochling J, Stucki G, Grill E, Braun J. A Comparative Study of Patient-Reported Functional Outcomes in Acute Rheumatoid Arthritis. *J Rheumatol* 2006 Nov 15; [Epub ahead of print]
280. Zochling J, Braun J. Remission in ankylosing spondylitis. *Clin Exp Rheumatol* 2006 Nov-Dec; 24(6 Suppl 43):S088-92
281. Braun J, Sieper J. Spondyloarthritides. *Z Rheumatol* 2006 Nov; 65(7):613-632
282. Braun J, Rudwaleit M, Hermann KG, Rau R. Imaging in ankylosing spondylitis. *Z Rheumatol* 2006 Oct 6; [Epub ahead of print]
283. Braun J, Sieper J. Early diagnosis of spondyloarthritis. *Nat Clin Pract Rheumatol* 2006 Oct; 2(10):536-45
284. van Echteld I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, van der Heijde D. Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. *J Rheumatol* 2006 Dec; 33(12):2475-83. Epub 2006 Oct 15.

285. Dybowski F, Jakobs B, Altmeyer P, Braun J. Successful treatment of clinical manifestations of Muckle-Wells syndrome with anakinra. *Dtsch Med Wochenschr* 2006 Aug 25; 131(34-35):1863-6.
286. van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, Bala M, Han J, Braun J. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. *Arthritis Rheum* 2006 Aug 15;55(4): 569-74.
287. Zochling J, Grill E, Scheuringer M, Liman W, Stucki G, Braun J. Identification of health problems in patients with acute inflammatory arthritis, using the International Classification of Functioning, Disability and Health (ICF). *Clin Exp Rheumatol* 2006 May-Jun; 24(3):239-46.
288. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006 Jul; 54(7): 2136-46.
289. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, van der Heijde D. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. *Arthritis Rheum* 2006 Apr 27; 54(5): 1646-1652 [Epub ahead of print]
290. Zochling J, Braun J. Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. *Expert Opin Pharmacother* 2006 May;7(7):869-83.
291. Braun J, Zochling J, Baraliakos X, Alten RH, Burmester GR, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gomor B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial. *Ann Rheum Dis* 2006 Apr 10; [Epub ahead of print]
292. Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. Infection and work stress are potential triggers of ankylosing spondylitis. *Clin Rheumatol* 2006 Apr 22; [Epub ahead of print]
293. Zochling J, Bonjean M, Grill E, Scheuringer M, Stucki G, Braun J. Systematic review of measures and their concepts used in published studies focusing on the treatment of acute inflammatory arthritis. *Clin Rheumatol* 2006 Apr 22; [Epub ahead of print]
294. Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey. *Clin Rheumatol*. 2006 Mar 10; [Epub ahead of print]
295. Braun J, Wassenberg S. Outcome parameters for use in psoriatic arthritis. *Z Rheumatol* 2006 Feb 24; [Epub ahead of print]
296. Stier-Jarmer M, Liman W, Stucki G, Braun J. Structures of acute rheumatic care. *Z Rheumatol*. 2006 Feb 16; [Epub ahead of print]
297. Alberding A, Stierle H, Brandt J, Braun J. Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis - results of an observational study. *Z Rheumatol*. 2006 Feb 10; [Epub ahead of print]
298. Davis Jr JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. The Definition of Disease Duration in Ankylosing Spondylitis: Reassessing the Concept. *Ann Rheum Dis*. 2006 Feb 7; [Epub ahead of print]

299. Pham T, Landewe RB, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde DM. An International Study on Starting TNF-blocking agents in Ankylosing Spondylitis (ISSAS). *Ann Rheum Dis* 2006 Feb 7; [Epub ahead of print]
300. Rau R, Wasserberg S, Backhaus M, Braun J, Edelmann E, Kellner H, Ostendorf B, Rudwaleit M, Sandrock D, Schalm J, Scherer A, Schmidt W. Imaging methods in rheumatology: imaging in psoriasis arthritis (PsA). *Z Rheumatol* 2006 Jan 20; [Epub ahead of print]
301. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. *Arthritis Rheum* 2006 Feb; 54(2):678-81.
302. Kohler S, Thiel A, Rudwaleit M, Sieper J, Braun J. CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects. *Clin Exp Rheumatol* 2005 Nov-Dec; 23(6): 840-846
303. Heldmann F, Brandt J, Schoppe H, Braun J. A 46-year-old-patient with granulomatous prostatitis, arthralgia and haemorrhagic rhinitis. *Dtsch Med Wochenschr* 2006 Jan 5; 131(1-2):22-5.
304. Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. *Clin Rheumatol* 2005 Dec 23; 1-11 [Epub ahead of print]
305. Braun J, Listing J, Sieper J. Reply. *Arthritis Rheum* 2005 Dec; 52(12): 4049-4050.
306. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis - a reassessment of the clinical history for classification and diagnosis. *Arthritis Rheum* 2006 Feb; 54(2):569-78
307. Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. *Arthritis Rheum* 2005 Dec 15; 53(6):856-63.
308. Zochling J, Braun J. Assessment of ankylosing spondylitis. *Clin Exp Rheumatol* 2005 Sep-Oct; 23(5 Suppl 39):S133-41.
309. Hermann KG, Landewe RB, Braun J, van der Heijde D. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary? *J Rheumatol* 2005 Oct; 32(10):2056-60.
310. Landewe RB, Hermann KG, van der Heijde D, Baraliakos X, Lambert RG, Ostergaard M, Rudwaleit M, Salonen DC, Braun J. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. *J Rheumatol* 2005 Oct; 32(10):2050-5.
311. van der Heijde D, Landewe RB, Hermann KG, Maksymowych WP, Rudwaleit M, O'Connor PJ, Braun J. Application of the OMERACT Filter to Scoring Methods for Magnetic Resonance Imaging of the Sacroiliac Joints and the Spine. Recommendations for a Research Agenda at OMERACT 7. *J Rheumatol* 2005 Oct; 32(10): 2042-7.
312. Bollow M, Hermann KG, Biedermann T, Sieper J, Schontube M, Braun J. Very early spondyloarthritis: where the inflammation in the sacroiliac joints starts. *Ann Rheum Dis*. 2005 Nov; 64(11):1644-6.

313. François RJ, Neure L, Sieper J, Braun J. Immunohistologic examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor α in two early cases and transforming growth factor β in three later stages. *Ann Rheum Dis*. 2006 Jun;65(6):713-20. Epub 2005 Oct 25
314. Davis JC Jr, Van der Heijde D, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, De Vries T, Tsuji WH. Baseline Factors That Influence ASAS 20 Response in Patients with Ankylosing Spondylitis Treated With Etanercept. *J Rheumatol* 2005 Sep; 32(9): 1751-1754.
315. Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. *Scand J Rheumatol* 2005 May-Jun; 34(3): 178-90.
316. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Ann Rheum Dis* 2005 Aug 26; [Epub ahead of print]
317. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis Jr JC, Dijkmans B, Dougados M, Geher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Bohm H, van Royen BJ, Braun J. ASAS/EULAR recommenddations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2005 Aug 26; [Epub ahead of print]
318. Meyer MF, Czaplewski H, Braun J, Hellmich B, Schatz H, Klein HH. Lack of a difference in increased capillary blood cell velocity in the skin over proximal interphalangeal joints between rheumatoid arthritis and osteoarthritis. *Microvasc Res*. 2005 Aug 9; [Epub ahead of print]
319. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First Update of the International ASAS Consensus Statement for the Use of Anti-TNF Agents in Patients with Ankylosing Spondylitis. *Ann Rheum Dis* 2005 Aug 11; [Epub ahead of print]
320. Braun J, Baraliakos X, Godolias G, Bohm H. Therapy of ankylosing spondylitis - a review. Part I: Conventional medical treatment and surgical therapy. *Scand J Rheumatol* 2005 Mar-Apr; 34(2):97-108.
321. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. *Rheumatology (Oxford)* 2005 Aug 9; [Epub ahead of print]
322. Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. *Rheumatology (Oxford)*. 2005 Aug 9; [Epub ahead of print]
323. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. *Arthritis Rheum* 2005 Jul 28; 52(8):2447-2451 [Epub ahead of print]
324. Boonen A, van der Heijde D, Severens J, Boendermaker A, Landewe R, Braun J, Brandt J, Sieper J, van der Linden S. Markov model into the cost-utility over five years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis. *Ann Rheum Dis* 2005 Jul 13; [Epub ahead of print]

325. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. *J Rheumatol* 2005 Jul; 32(7): 1290-8.
326. Zochling J, Braun J. Management and treatment of ankylosing spondylitis. *Curr Opin Rheumatol*. 2005 Jul; 17(4):418-25.
327. Leistner K, Stier-Jarmer M, Berleth B, Braun J, Koenig E, Liman W, Luttje D, Meindl R, Pientka L, Weber G, Stucki G. Early Rehabilitation Care in the Acute Hospital Setting - Definition and Indication. *Rehabilitation (Stuttg)* 2005 Jun; 44(3): 165-175
328. Braun J. Infliximab in ankylosing spondylitis: a viewpoint. *Drugs* 2005; 65(9): 1292-4
329. Baraliakos X, Landewé R, Hermann KG, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. *Ann Rheum Dis* 2005 May;64(5):730-4. Epub 2004 Sep 30.
330. Davis Jr JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. *Ann Rheum Dis* 2005 Apr 20; [Epub ahead of print]
331. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther* 2005; 7(3):113. Epub 2005 Mar 23.
332. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. *Arthritis Rheum* 2005 Apr 7; 52(4):1216-1223 [Epub ahead of print]
333. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis before and during therapy with etanercept. *Ann Rheum Dis* 2005 Mar 18; [Epub ahead of print]
334. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor- α antibody infliximab. *Ann Rheum Dis* 2005 Mar 18; [Epub ahead of print]
335. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J. Persistent clinical response to the anti-TNF- α antibody infliximab in patients with ankylosing spondylitis over 3 years. *Rheumatology (Oxford)* 2005 Mar 15; [Epub ahead of print]
336. Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split ? *Ann Rheum Dis* 2005 Mar; 64 Suppl 2: ii9-13.
337. van der Heijde D, Braun J, Landewe R, Davis J, Sieper J, van der Linden S, Dougados M. ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis ? *Ann Rheum Dis* 2005 Mar; 64 Suppl 2: ii108-9.
338. van der Heijde D, Dijkmans B, Geusens P, Sieper J, Dewoody K, Williamson P, Braun J. Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum* 2005 Feb 3; 52(2): 582-591 [Epub ahead of print]

339. van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, Hallegua DS, Bruckel J. Assessments in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. *Arthritis Rheum* 2005 Feb 3; 52(2):386-394 [Epub ahead of print]
340. Baraliakos X, Hermann KG, Landewe R, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging (MRI): a comparison between contrast enhanced T1 and short-tau inversion recovery (STIR) sequences. *Ann Rheum Dis* 2005 Feb 11; [Epub ahead of print]
341. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. *Ann Rheum Dis*. 2005 Jan; 64(1):124-6.
342. Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing pondylitis. *Rheumatology (Oxford)* 2004 Nov 23
343. Schneider M, Lelgemann M, Baerwald C, Braun J, Hammer M, Kern P, Krause A, Alten R, Faubel U, Hammer M, Lakomek J, Liman W, Pauly T, Schnabel A. Value of inpatient care in rheumatoid arthritis-an evidence based report. *Z Rheumatol* 2004 Oct; 63(5): 402-13.
344. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. *Ann Rheum Dis* 2004 Dec; 63(12):1670-1672.
345. Haibel H, Niewerth M, Brandt J, Rudwaleit M, Listing J, Sieper J, Braun J. Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12. *Z Rheumatol* 2004 Oct; 63(5):393-401.
346. Appel H, Neure L, Kuhne M, Braun J, Rudwaleit M, Sieper J. An elevated level of IL-10- and TGF β -secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. *Clin Rheumatol* 2004 Oct; 23(5): 435-40. Epub 2004 Jul 28.
347. Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Inflammation in ankylosing spondylitis - a systematic description of the extension and frequency of acute spinal changes using magnetic resonance imaging (MRI). *Ann Rheum Dis* 2004 Sep 30; [Epub ahead of print]
348. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sørensen H, Zeidler H, Reddig J, Sieper J. Two-Year Maintenance of Efficacy and Safety of Infliximab in the Treatment of Ankylosing Spondylitis. *Ann Rheum Dis* 2004 Sep 23 (epub)
349. Baraliakos X, Braun J. Current concepts in the therapy of the spondyloarthritides. *BioDrugs* 2004; 18(5):307-14.
350. Braun J, Sieper J. Reply. *Arthritis Rheum* 2004 Jul; 50(7): 2377-2378.
351. Peloso PM, Braun J. Expanding the armamentarium for the spondyloarthropathies. *Arthritis Res Ther* 2004; 6 Suppl 2:S36-43.
352. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab. *Rheumatology (Oxford)* 2004 Jun 29

353. Franck H, Braun J, Buttgereit F, Dreher R, Hein G, Kekow J. Specialities in therapy of osteoporosis in inflammatory joint disease. *Z Rheumatol* 2004 Jun; 63(3): 223-9.
354. Brandt J, Sieper J, Braun J. Current therapy with TNF α blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis. *Z Rheumatol* 2004 Jun; 63(3):203-10.
355. Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. *Rheumatology (Oxford)* 2004 Jun 8
356. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. *Ann Rheum Dis* 2004 May; 63(5):535-43.
357. Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J, Rudwaleit M, Zuhlsdorf S, Bollow M, Sieper J, van der Heijde D. Analysing chronic spinal changes in ankylosing spondylitis - a systematic comparison of conventional x- rays with magnetic resonance imaging (MRI) using established and new scoring systems. *Ann Rheum Dis*. 2004 Apr 28 Epub 2004 Apr 05.
358. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short-term improvement after anti-TNF α therapy in ankylosing spondylitis. *Ann Rheum Dis* 2004 Mar 25
359. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to TNF- α blockers in ankylosing spondylitis. *Ann Rheum Dis* 2004 Mar 22
360. Sieper J, Zou J, Rudwaleit M, Braun J. Reply. *Arthritis Rheum* 2004 Mar; 50(3): 1017
361. Braun J. Epidemiology and prognosis of ankylosing spondylitis. *Radiologe* 2004 Mar; 44(3): 209-10, 212-6.
362. Hermann KG, Braun J, Fischer T, Reisschauer H, Bollow M. Magnetic resonance imaging of sacroiliitis: anatomy, histological pathology, MR-morphology, and grading. *Radiologe* 2004 Mar; 44(3):217-28.
363. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor- α fusion receptor protein etanercept. *J Rheumatol* 2004 Mar;31(3):531-8.
364. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W and the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis Rheum* 2003 Nov; 48(11): 3230-6.
365. Braun J, Sieper J, van der Heijde D. Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. *Ann Rheum Dis* 2003 Oct; 62(10):1023-4.
366. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D for the ASAS working group. International ASAS consensus statement for the use of biologic agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2003, Sep; 62(9): 817-24
367. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. *Arthritis Rheum* 2003 Aug; 48(8): 2224-33

368. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the non-specific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. *Arthritis Rheum* 2003 Mar; 48(3): 780-90
369. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor- α and interferon- γ by T cells in ankylosing spondylitis during treatment with etanercept. *Ann Rheum Dis* 2003 Jun; 62(6):561-4
370. Zou J, Zhang Y, Thiel A, Rudwaleit M, Shi SL, Radbruch A, Poole R, Braun J, Sieper J. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. *Rheumatology (Oxford)* 2003 Jul; 42(7): 846-55
371. Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J. Treatment of active ankylosing spondylitis with pamidronate. *Rheumatology (Oxford)* 2003 Aug; 42(8): 1018-20.
372. Braun J, Sieper J. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. *BioDrugs* 2003; 17(3):187-99
373. Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides: Expert Opin Investig Drugs 2003 Jul; 12(7): 1097-109
374. Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. *Expert Opin Biol Ther* 2003 Feb;3(1):141-68
375. Braun J, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J. Biologic therapies in the spondylarthropathies: new opportunities, new challenges. *Curr Opin Rheumatol* 2003 Jul; 15(4):394-407.
376. Brandt J, Sieper J, Braun J. Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF- α -antagonists. *Z Rheumatol* 2003 Jun; 62(3): 218-27
377. Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J. Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. *Z Rheumatol* 2003 Jun; 62(3): 264-73.
378. Fischer T, Biedermann T, Hermann KG, Diekmann F, Braun J, Hamm B, Bollow M. Sacroiliitis in children with spondyloarthropathy: therapeutic effect of CT-Guided intra-articular corticosteroid injection. *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* 2003 Jun; 175(6): 814-21.
379. Brandt J, Kariouzov A, Listing J, Haibel H, Sørensen H, Grassnickel L, Sieper J, Braun J. Six months results of a German double-blind placebo controlled clinical Trial of Etanercept in active Ankylosing Spondylitis. *Arthritis Rheum* 2003 Jun; 48(6): 1667-75
380. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, van der Heijde D. MRI examinations of the spine in patients with ankylosing spondylitis (AS) before and after infliximab therapy after evaluation of a new scoring system. *Arthritis Rheum* 2003, Apr;48(4):1126-36
381. Muche B, Bollow M, François RJ, Sieper J, Hamm B, Braun J. Which anatomical structures are involved in early and late sacroiliitis in spondyloarthritis – a detailed analysis by contrast enhanced magnetic resonance imaging. *Arthritis Rheum* 2003, May; 48(5): 1374-84
382. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol Int* 2003 Mar;23(2): 61-6.

383. Braun J, Sieper J. Role of novel biologic therapies in psoriatic arthritis – effects on joints and skin. *BioDrugs* 2003; 17(3): 187-99
384. Van Tubergen A, van Der Heijde D, Anderson J, Landewe R, Dougados M, Braun J, Bellamy N, Udrea G, van Der Linden S. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. *Ann Rheum Dis* 2003 Mar; 62(3):215-221
385. Sieper J, Braun J. Anti-TNF agents for the treatment of spondyloarthropathies. *Expert Opin Emerg Drugs* 2002 Oct; 7(2):235-46.
386. Braun J, Sieper J. Anti-TNF therapy and the spondyloarthritides: who should be treated? *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28): S187
387. Braun J, Golder W, Bollow M, Sieper J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28): S178-84.
388. Bollow M, Enzweiler C, Taupitz M, Golder W, Hamm B, Sieper J, Braun J. Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28):S167-74.
389. Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28):S106-10
390. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28):S34-7
391. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28):S16-22
392. Lautermann D, Braun J. Ankylosing spondylitis - cardiac manifestations. *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28):S11-5
393. Braun J, van der Heijde D, Pincus T. Novel anti-rheumatic therapies challenge old views on ankylosing spondylitis and other spondyloarthritides. *Clin Exp Rheumatol* 2002 Nov-Dec; 20(6 Suppl 28): S1-2
394. Backhaus M, Schmidt WA, Mellerowicz H, Bohl-Buhler M, Banzer D, Braun J, Sattler H, Hauer RW. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology. Part 6: Ultrasonography of the wrist/hand. *Z Rheumatol* 2002 Dec; 61(6): 674-87
395. Backhaus M, Schmidt WA, Mellerowicz H, Bohl-Buhler M, Banzer D, Braun J, Sattler H, Hauer RW. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology. Part 6: Ultrasonography of the elbow. *Z Rheumatol* 2002 Aug; 61(4):415-25
396. Karow AC, Braun J, Marx P, Stangel M. Remission of a CNS inflammatory disease accompanied by newly developed ANA and arthropathy during treatment with IFN-beta. *J Neurol* 2002 Aug; 249(8): 1121-2
397. Braun J, Breban M, Maksymowych WP. Therapy for ankylosing spondylitis: new treatment modalities. *Best Pract Res Clin Rheumatol* 2002 Sep; 16(4): 631-51
398. Maksymowych WP, Breban M, Braun J. Ankylosing spondylitis and current disease-controlling agents: do they work? *Best Pract Res Clin Rheumatol* 2002 Sep; 16(4): 619-30.
399. Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. *Best Pract Res Clin Rheumatol* 2002 Sep; 16(4):573-604.
400. Mellerowicz H, Hauer RW, Schmidt WA, Bohl-Buhler M, Banzer D, Sattler H, Braun J, Backhaus M. Technique and diagnostic value of musculoskeletal ultrasonography

in rheumatology. Part 5: Ultrasonography of the shoulder. *Z Rheumatol* 2002 Oct; 61(5): 577-89.

401. Braun J, Sieper J. Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. *Ann Rheum Dis* 2002 Nov; 61 Suppl 3:III61-III67
402. Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. *Ann Rheum Dis* 2002 Nov; 61 Suppl 3:III51-III60
403. Van Der Heijde D, Braun J, McGonagle D, Siegel J. Treatment trials in ankylosing spondylitis: current and future considerations. *Ann Rheum Dis* 2002 Nov; 61 Suppl 3:III24-III32.
404. Braun J, Van Der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, Van Der Linden S. Staging of patients with ankylosing spondylitis: a preliminary proposal. *Ann Rheum Dis* 2002 Nov; 61 Suppl 3:III19-III23.
405. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. *Ann Rheum Dis* 2002 Nov; 61 Suppl 3:III8-III18.
406. Sieper J, Braun J. New treatment strategies in ankylosing spondylitis: Proceedings of the Ankylosing Spondylitis Workshop, Berlin, Germany, 18-19 January 2002. *Ann Rheum Dis* 2002 Nov; 61 Suppl 3:III1-III2.
407. Rudwaleit M, Andermann B, Alten R, Sorensen H, Listing J, Zink A, Sieper J, Braun J. Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. *Ann Rheum Dis* 2002 Nov; 61(11):968-974
408. Sieper J, Braun J. Diagnosis and antibiotic treatment of reactive arthritis. *Dtsch Med Wochenschr* 2002 Sep 13; 127(37):1893-6.
409. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. *Arthritis Res* 2002; 4(5):307-21.
410. Schmidt WA, Hauer RW, Banzer D, Bohl-Buhler M, Braun J, Mellerowicz H, Sattler H, Backhaus M. *Z Rheumatol* 2002 Jun; 61(3):279-90.
411. Schneider P, Grone J, Braun J, Perez-Canto A, Buhr HJ. Wegener's granulomatosis presenting as necrosis of the left mainstem bronchus. *Asian Cardiovasc Thorac Ann* 2002 Sep;10(3):277-9
412. Braun J, Sieper J. New and old therapeutic options in ankylosing spondylitis - is there an indication for sulfasalazine? *Z Rheumatol* 2002 Apr; 61(2):151-8
413. Schmidt WA, Hauer RW, Banzer D, Bohl-Buhler M, Braun J, Mellerowicz H, Sattler H, Backhaus M. Ultrasound of the hip joints. *Z Rheumatol* 2002 Apr; 61(2):180-8.
414. Feldtkeller E, Braun J. Prevalence of spondyloarthropathy in Japan. *J Rheumatol* 2002 May; 29(5):1105-7
415. Haibel H, Rudwaleit M, Braun J, Sieper J. Quality of life in AS. *Z Rheumatol* 2002 Feb; 61(1):30-8.
416. Zou J, Rudwaleit M, Thiel A, Lauster R, Braun J, Sieper J. T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesis. *Ann Rheum Dis* 2002 May; 61(5): 473-4
417. Braun J, Brandt J, Listing J, Golder W, Alten R, Burmester GR, Gromnica-Ihle E, Kellner H, Schneider M, Sørensen H, Zeidler H, Thriene W, Sieper J. Treatment of

- active ankylosing spondylitis with infliximab - a double-blind placebo controlled multicenter trial. *Lancet* April 6th 2002, 359:1187-93
418. Brandt J, Maier T, Rudwaleit M, Kuhl U, Hiepe F, Sieper J, Braun J. Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjogren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis. *Clin Exp Rheumatol* 2002 Jan-Feb; 20(1):80-4
 419. Sieper J, Rudwaleit M, Braun J, van Der Heijde D. Diagnosing reactive arthritis: Role of clinical setting in the value of serologic and microbiologic assays. *Arthritis Rheum* 2002 Feb; 46(2):319-27
 420. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor- α monoclonal antibody infliximab. *J Rheumatol* 2002 Jan; 29(1):118-22
 421. Machein U, Buss B, Spiller I, Braun J, Rudwaleit M, Faerber L, Sieper J. Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. *Rheumatology (Oxford)* 2002 Jan; 41(1):110-1
 422. Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. *Arthritis Rheum* 2001 Dec; 44(12): 2936-7
 423. Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNF α therapy. *Ann Rheum Dis* 2001 Nov; 60 Suppl 3:iii58-61
 424. Sieper J, Braun J. Innovative Therapie der Spondyloarthritiden. *Z Rheumatol* 2001 Dec; 60(6):458-63
 425. Rudwaleit M, Richter S, Braun J, Sieper J. Low incidence of reactive arthritis in children following a salmonella outbreak. *Ann Rheum Dis* 2001 Nov; 60(11): 1055-7
 426. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. *Curr Opin Rheumatol* 2001 Jul; 13(4):245-9
 427. Francois RJ, Braun J, Khan MA. Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. *Curr Opin Rheumatol* 2001 Jul; 13(4):255-64
 428. Braun J, Sieper J. Glucocorticoid-induced osteoporosis. *Orthopäde* 2001 Jul; 30(7): 444-50
 429. Hauer RW, Schmidt WA, Bohl-Buhler M, Banzer D, Mellerowicz H, Sattler H, Braun J, Backhaus M. Technique and value of arthrosonography in rheumatologic diagnosis. 1: Ultrasound diagnosis of the knee joint. *Z Rheumatol* 2001 Jun; 60(3): 139-47
 430. Golder W, Schnorfeil M, Braun J, Dollinger P. Non-neoplastic hypertrophic osteoarthropathy due to infected aortic prosthesis. Diagnostic imaging aspects. *Radiologe* 2001 May; 41(5):447-53
 431. Scharla SH, Buttgereit F, Dreher R, Felsenberg D, Franck H, Hein G, Lemmel EM, Rau R, Sieper J, Braun J. Preliminary consensus statement on glucocorticoid-induced osteoporosis. *Z Rheumatol* 2001 Apr; 60(2):96-9
 432. Braun J. Epidemiology of corticosteroid-induced osteoporosis. *Z Rheumatol* 2001 Apr; 60(2):107-10
 433. Braun J, Lemmel EM, Manger B, Rau R, Sorensen H, Sieper J. Therapy of ankylosing spondylitis (AS) with radium chloride (224SpondylAT). *Z Rheumatol* 2001 Apr; 60(2): 74-83
 434. Braun J, Buttgereit F, Felsenberg D, Sieper J. Pathogenesis and therapy of steroid-induced osteoporosis. *Z Rheumatol*. 2001 Apr;60(2):100-3
 435. Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Groh A, Uksila J, Granfors K, Braun J, Sieper J. Frequency of triggering bacteria in patients with reactive arthritis

- and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. *Ann Rheum Dis* 2001 Apr; 60(4):337-43
436. Thiel A, Wu P, Lauster R, Braun J Radbruch A, Sieper J. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. *Arthritis Rheum* 2000 Dec; 43(12):2834-42
 437. Sturzenbecher A, Braun J, Paris S, Biedermann T, Hamm B, Bollow M. MR imaging of septic sacroiliitis. *Skeletal Radiol* 2000 Aug; 29(8):439-46
 438. Halank M, Rubens C, Ewert R, Hoffken G, Braun J. Severe precapillary pulmonary hypertension in possible antiphospholipid syndrome - partially successful long-term therapy with continuous intravenous iloprost administration. A case report with discussion of new treatment methods. *Z Rheumatol* 2000 Oct; 59(5): 334-42
 439. Rudwaleit M, Siepert S, Yin Z, Eick J, Thiel A, Radbruch A, Sieper J, Braun J. Low T cell production of TNF α and IFN γ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. *Ann Rheum Dis* 2001 Jan; 60(1):36-42
 440. Braun J, Bollow M. Imaging of inflammatory rheumatic diseases of the axial skeleton (sacroiliitis): when and how should we use MRI ? *J Clin Rheumatol* 2000; 6:339-350
 441. Feldtkeller E, Braun J. Impact of sex on inheritance of ankylosing spondylitis. *The Lancet* 2000 Mar 25; 355(9209):1096-7
 442. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. *J Rheumatol* 2000 Mar; 27(3):613-22
 443. Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? *Ann Rheum Dis* 2000 Dec; 59(12): 985-94
 444. Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, Kohler S, Rudwaleit M, Siepert S, Radbruch A, Thiel A, Sieper J. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor- α : first clinical and laboratory experiences. *Ann Rheum Dis* 2000 Nov; 59 Suppl 1:i85-9
 445. Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th Int. Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999 *J Rheumatol* 2000 Sep; 27(9): 2185-92
 446. Alenfeld FE, Diessel E, Brezger M, Sieper J, Felsenberg D, Braun J. Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. *Osteoporos Int* 2000; 11(5): 400-7
 447. Liangos O, Neure L, Kuhl U, Pauschinger M, Sieper J, Distler A, Schwimmbeck PL, Braun J. The possible role of myocardial biopsy in systemic sclerosis. *Rheumatology (Oxford)* 2000 Jun; 39(6): 674-9
 448. Braun J, Sieper J. Inception cohorts for spondyloarthropathies. *Z Rheumatol* 2000 Apr; 59(2): 117-21
 449. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. *Arthritis Rheum* 2000 Jun; 43(6):1346-52
 450. Braun J, Sieper J. Anti-TNF α : a new dimension in the pharmacotherapy of the spondyloarthropathies !? *Ann Rheum Dis* 2000 Jun; 59(6):404-7

451. Sieper J, Braun J, Kingsley GH. Report on the Fourth International Workshop on Reactive Arthritis. *Arthritis Rheum* 2000 Apr; 43(4): 720-34
452. Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. *Clin Rheumatol* 2000; 19(1): 51-7
453. Rudwaleit M, Yin Z, Siepert S, Grolms M, Radbruch A, Braun J, Sieper J. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. *Ann Rheum Dis* 2000 Apr; 59(4):311-4
454. Bollow M, Fischer T, Reissbauer H, Backhaus M, Sieper J, Hamm B, Braun J. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. *Ann Rheum Dis* 2000 Feb; 59(2):135-40
455. Mertz AK, Wu P, Sturniolo T, Stoll D, Rudwaleit M, Lauster R, Braun J, Sieper J. Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of *Yersinia enterocolitica* in *Yersinia*-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. *J Immunol* 2000 Feb 1; 164(3): 1529-37
456. Rudwaleit M, Braun J, Sieper J. Treatment of reactive arthritis: a practical guide. *BioDrugs* 2000 Jan; 13(1): 21-8.
457. Yin Z, Siepert S, Neure L, Grolms M, Liu L, Eggens U, Radbruch A, Braun J, Sieper J. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor- β . *Rheumatology (Oxford)*. 1999 Nov; 38(11): 1058-67
458. Braun J, Sieper J. Cytokines and the immunopathology of the spondyloarthropathies. *Curr Rheumatol Rep* 1999 Oct;1(1): 67-77
459. Petermann A, Tebbe B, Distler A, Sieper J, Braun J. Sweet's syndrome in a patient with acute Crohn's colitis and longstanding ankylosing spondylitis. *Clin Exp Rheumatol* 1999 Sep-Oct; 17(5): 607-10
460. Braun J, Yin Z, Spiller I, Siepert S, Rudwaleit M, Liu L, Radbruch A, Sieper J. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. *Arthritis Rheum* 1999 Oct; 42(10): 2039-44
461. Jung C, Wagner J, Heine B, Sieper J, Distler A, Braun J. Abdominal actinomycosis after stomach surgery in a patient with long-term rheumatoid arthritis treated with methotrexate. *Dtsch Med Wochenschr*. 1999 Sep 17; 124(37): 1066-70
462. Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A, Sieper J, Braun J. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. *Rheumatology (Oxford)* 1999 Sep; 38(9): 831-6.
463. Braun J, Sieper J. New aspects of treatment and prophylaxis of gastrointestinal side effects caused by non-steroidal-antiinflammatory drugs. *Z Rheumatol* 1999 Aug; 58(4): 173-84
464. Appel H, Mertz A, Distler A, Sieper J, Braun J. The 19 kDa protein of *Yersinia enterocolitica* O:3 is recognized on the cellular and humoral level by patients with *Yersinia* induced reactive arthritis. *J Rheumatol* 1999 Sep; 26(9):1964-71
465. Sieper J, Braun J. Reactive arthritis. *Curr Opin Rheumatol* 1999 Jul; 11(4):238-43

466. Braun J, Sieper J. 25 years HLA B27--report on the "B27 and Beyond" NIH Conference. *Z Rheumatol* 1999 Apr; 58(2):104-8
467. Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, Alten R, Keitel W, Groh A, Uksila J, Eggens U, Granfors K, Braun J. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. *Arthritis Rheum* 1999 Jul; 42(7): 1386-96
468. Sieper J, Braun J. Problems and advances in the diagnosis of reactive arthritis. *J Rheumatol* 1999 Jun; 26(6): 1222-4
469. Bollow M, Loreck D, Banzer D, Brandt H, Zerbes K, Kourik W, Mellorowicz H, Backhaus M, Schmidt W, Bohl-Buhler M, Hauer R, Eggens U, Braun J. Imaging diagnosis in suspected inflammatory rheumatoid axial skeleton diseases (sacroilitis). *Z Rheumatol* 1999 Apr; 58(2): 61-70
470. Rudwaleit M, Braun J. Reply. *Arthritis Rheum* 1999 Apr; 42(4):832
471. Wilkinson NZ, Kingsley GH, Jones HW, Sieper J, Braun J, Ward ME. The detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. *Rheumatology (Oxford)* 1999 Mar; 38(3): 260-6
472. Braun J, Sieper J. Spondyloarthropathy. *Lancet* 1999 May 1; 353(9163):1526-7
473. Braun J, Sieper J, Riemekasten G, Hiepe F. Iloprost treatment in systemic sclerosis: comment on the concise communication by Tedeschi et al. *Arthritis Rheum* 1999 Jan; 42(1):196-8
474. Braun J, Sieper J. Rheumatologic manifestations of gastrointestinal disorders. *Curr Opin Rheumatol* 1999 Jan; 11(1): 68-74
475. Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. *Rheum Dis Clin North Am.* 1998 Nov; 24(4): 697-735
476. Rudwaleit M, Elias F, Humaljoki T, Neure L, Knauf W, Stein H, Distler A, Sieper J, Berek C, Braun J. Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case report. *Arthritis Rheum* 1998 Sep; 41(9): 1695-700
477. Fendler C, Wu P, Eggens U, Laitko S, Sorensen H, Distler A, Braun J, Sieper J. Longitudinal investigation of bacterium-specific synovial lymphocyte proliferation in reactive arthritis and lyme arthritis. *Br J Rheumatol* 1998 Jul; 37(7): 784-8
478. Sieper J, Braun J. Treatment of reactive arthritis with antibiotics. *Br J Rheumatol* 1998 Jul; 37(7):717-20
479. Fendler C, Braun J, Eggens U, Laitko S, Sorensen H, Distler A, Sieper J. Bacteria-specific lymphocyte proliferation in peripheral blood in reactive arthritis and related diseases. *Br J Rheumatol* 1998 May; 37(5): 520-4
480. Wilkinson NZ, Kingsley GH, Sieper J, Braun J, Ward ME. Lack of correlation between the detection of *Chlamydia trachomatis* DNA in synovial fluid from patients with a range of rheumatic diseases and the presence of an anti-chlamydial immune response. *Arthritis Rheum* 1998 May; 41(5): 845-54
481. Brandt J, Rudwaleit M, Eggens U, Mertz A, Distler A, Sieper J, Braun J. Increased frequency of Sjogren's syndrome in patients with spondyloarthropathy. *J Rheumatol* 1998 Apr; 25(4): 718-24
482. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J. A single nonamer from the *Yersinia* 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in *Yersinia*-induced reactive arthritis. *J Immunol* 1997 Dec 1; 159(11): 5715-23

483. Bollow M, Biedermann T, Kannenberg J, Paris S, Schauer-Petrowski C, Minden K, Schontube M, Hamm B, Sieper J, Braun J. Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. *J Rheumatol* 1998 Mar; 25(3): 556-64
484. Bollow M, Braun J, Biedermann T, Mutze S, Paris S, Schauer-Petrowskaja C, Minden K, Schmitz SA, Schoentube M, Hamm B. Use of contrast-enhanced MR imaging to detect sacroiliitis in children. *Skeletal Radiol* 1998 Nov; 27(11): 606-16
485. Mertz AK, Ugrinovic S, Lauster R, Wu P, Grolms M, Bottcher U, Appel H, Yin Z, Schiltz E, Batsford S, Schauer-Petrowski C, Braun J, Distler A, Sieper J. Characterization of the synovial T cell response to various recombinant Yersinia antigens in Yersinia enterocolitica-triggered reactive arthritis. Heat-shock protein 60 drives a major immune response. *Arthritis Rheum* 1998 Feb; 41(2): 315-26
486. Appel H, Sieper J, Golder W, Hiepe F, Distler A, Braun J. Autoantibodies against centrosomes in a patient with limited systemic sclerosis with ulcera cruris and arteriopathy - case report and review of the literature. *Z Rheumatol* 1997 Oct; 56(5): 298-305
487. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. *Arthritis Rheum* 1998 Jan; 41(1):58-67
488. Bollow M, Braun J, Kannenberg J, Biedermann T, Schauer-Petrowskaja C, Paris S, Mutze S, Hamm B. Normal morphology of sacroiliac joints in children: magnetic resonance studies related to age and sex. *Skeletal Radiol* 1997 Dec; 26(12):697-704
489. Braun J, Sieper J. The clinical concept of spondyloarthropathies. *Fortschr Med* 1997 Sep 20; 115(26): 44-5
490. Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, Sieper J. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. *Arthritis Rheum* 1997 Oct; 40(10): 1788-97
491. Braun J, Tuszewski M, Ehlers S, Haberle J, Bollow M, Eggens U, Distler A, Sieper J. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. *J Rheumatol* 1997 Jun; 24(6): 1101-5
492. Braun J, Tuszewski M, Eggens U, Mertz A, Schauer-Petrowskaja C, Doering E, Laitko S, Distler A, Sieper J, Ehlers S. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides. *J Rheumatol* 1997 Jun; 24(6): 1092-100
493. Hemmen T, Stolzel U, Hoffken G, Vesper J, Sieper J, Distler A, Braun J. Costosternal swelling and diffuse bone pain in tubercular osteomyelitis. *Dtsch Med Wochenschr* 1997 May 9; 122(19): 610-4
494. Braun J, Sieper J. Comment on the article 'Reactive arthritis, beta-haemolytic Streptococcus and Staphylococcus aureus' by D. N. Leitch and C. D. Holland. *Br J Rheumatol* 1997 May; 36(5): 606-7
495. Kuon W, Lauster R, Bottcher U, Koroknay A, Ulbrecht M, Hartmann M, Grolms M, Ugrinovic S, Braun J, Weiss EH, Sieper J. Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice. *Arthritis Rheum* 1997 May; 40(5): 945-54

496. Appel H, Sieper J, Distler A, Braun J. Severe destructive beta 2-microglobulin arthropathy after 28 years of hemodialysis. *Arthritis Rheum* 1997 Apr;40(4): 709
497. Bollow M, Braun J, Hamm B. Sacroiliitis: the key symptom of spondyloarthropathies. 1. The clinical aspects. *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr.* 1997 Feb; 166(2):95-100
498. Giemsa U, Sieper J, Braun J, Mitchison NA. Type II collagen serology: a guide to clinical responsiveness to oral tolerance? *Rheumatol Int* 1997; 16(6): 237-40
499. Yin Z, Braun J, Neure L, Wu P, Eggens U, Krause A, Kamradt T, Sieper J. T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. *Arthritis Rheum* 1997 Jan; 40(1): 69
500. Braun J, Sieper J. Explanatory models for HLA-B27 association of reactive arthritis as a paradigm for spondyloarthropathy. *Med Klin* 1996 Sep 15; 91(9): 574-9
501. Bollow M, Braun J, Taupitz M, Haberle J, Reibhauer BH, Paris S, Mutze S, Seyrekbasan F, Wolf KJ, Hamm B. CT-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with spondyloarthropathy: indication and follow-up with contrast-enhanced MRI. *J Comput Assist Tomogr* 1996 Jul-Aug; 20(4): 512-21
502. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. *Curr Opin Rheumatol* 1996 Jul; 8(4): 275-87
503. Sieper J, Braun J. Therapy of rheumatoid arthritis. *Dtsch Med Wochenschr* 1996 Apr 26; 121(17): 563-7
504. Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A, Distler A, Sieper J. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. *J Rheumatol* 1996 Apr 23(4): 659-64
505. Braun J, Sieper J. Commented glossary for rheumatic spinal diseases. *Ann Rheum Dis.* 1996 Jan; 55(1): 76; discussion 77-8
506. Sieper J, Kary S, Sorensen H, Alten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. *Arthritis Rheum* 1996 Jan; 39(1): 41-51
507. Sieper J, Braun J. Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? *Arthritis Rheum* 1995 Nov; 38(11): 1547-54
508. Bollow M, Braun J, Hamm B, Eggens U, Schilling A, König H, Wolf KJ. Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. *Radiology* 1995 Feb; 194(2): 529-36
509. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. *Arthritis Rheum* 1995 Apr; 38(4): 499-505
510. Brandt J, Braun J, Koenig H, Sieper J. Sapho syndrome: 2 case reports. *Aktuelle Radiol* 1995 Jan; 5(1): 56-8
511. Mertz AK, Daser A, Skurnik M, Wiesmüller KH, Braun J, Appel H, Batsford S, Wu P, Distler A, Sieper J. The evolutionarily conserved ribosomal protein L23 and the cationic urease beta-subunit of *Yersinia enterocolitica* O:3 belong to the immunodominant antigens in *Yersinia*-triggered reactive arthritis: implications for autoimmunity. *Mol Med* 1994 Nov; 1(1): 44-55

512. Wacker F, Schilling A, Braun J, Bollow M, König H, Wolf KJ. Rheumatoid arthritis of the hand. The initial results with 31-phosphorus MR spectroscopy. *Röfo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr* 1994 Jun; 160(6): 559-63
513. Braun J, Grolms M, Distler A, Sieper J. The specific antibacterial proliferation of reactive arthritis synovial T cells is not due to their higher proportion of CD45 RO+ cells compared to peripheral blood. *J Rheumatol* 1994 Sep; 21(9): 1702-7
514. Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. *Arthritis Rheum* 1994 Jul; 37(7): 1039-45
515. Braun J, Laitko S, Treharne J, Eggens U, Wu P, Distler A, Sieper J. Chlamydia pneumoniae - a new causative agent of reactive arthritis and undifferentiated oligoarthritis. *Ann Rheum Dis* 1994 Feb; 53(2): 100-5
516. Braun J, Grolms M, Sieper J. Three-colour flowcytometric examination of CD4/CD45 subsets reveals no differences in peripheral blood and synovial fluid between patients with reactive arthritis and rheumatoid arthritis. *Clin Exp Rheumatol* 1994 Jan-Feb; 12(1): 17-22
517. Braun J, Eggens U, Sieper J. Principles of therapy in reactive arthritis. *Wien Klin Wochenschr* 1994; 106(9): 259-64
518. Simon AK, Seipelt E, Wu P, Wenzel B, Braun J, Sieper J. Analysis of cytokine profiles in synovial T cell clones from chlamydial reactive arthritis patients: predominance of the Th1 subset. *Clin Exp Immunol* 1993 Oct; 94(1): 122-6
519. Sieper J, Braun J, Wu P, Hauer R, Laitko S. The possible role of Shigella in sporadic enteric reactive arthritis. *Br J Rheumatol* 1993 Jul; 32(7): 582-5
520. Braun J, Döring E, Wu P, Heesemann J, Treharne J, Eggens U, Sieper J. Synovial cellular immune response to bacterial pathogens in patients with chronic juvenile arthritis. *Z Rheumatol* 1993 Jul-Aug; 52(4): 201-9
521. Sieper J, Braun J, Reichardt M, Eggens U. The value of specific antibody detection and culture in the diagnosis of reactive arthritis. *Clin Rheumatol* 1993 Jun; 12(2): 245-52
522. Sieper J, Braun J. The diagnosis of reactive arthritis. The possibilities and limits. *Dtsch Med Wochenschr* 1993 May 14; 118(19): 712-8
523. Bollow M, Braun J, König H, Schilling A, Wacker F, Seyrekbasan VF, Eggens U, Wolf KJ. Dynamic magnetic resonance tomography of the sacroiliac joint: diagnosis of the early stages of a sacroiliitis. *Roentgenpraxis* 1994 Mar; 47(3): 70-7
524. Braun J, Sieper J, Schwarz A, Hiepe F, Lenz T, Keller F, Herbst H, Distler A. Widespread vasculopathy with hemolytic uremic syndrome, perimyocarditis and cystic pancreatitis in a young woman with mixed connective tissue disease. Case report and review of the literature. *Rheumatol Int* 1993; 13(1): 31-6
525. Sieper J, Braun J, Wu P, Kingsley G. T cells are responsible for the enhanced synovial cellular immune response to triggering antigen in reactive arthritis. *Clin Exp Immunol* 1993 Jan; 91(1): 96-102
526. Sieper J, Braun J, Laitko S, Sørensen H, Wu P, Mielke M, Heesemann J. Reactive arthritis associated bacteria as the etiology of undifferentiated oligoarthritis. *Z Rheumatol* 1993 Jan-Feb; 52(1): 19-27
527. Sieper J, Braun J, Döring E, Wu P, Heesemann J, Treharne J, Kingsley G. Aetiological role of bacteria associated with reactive arthritis in pauciarticular juvenile chronic arthritis. *Ann Rheum Dis*. 1992 Nov; 51(11): 1208-14

528. Sieper J, Braun J, Wu P, Kingsley G. Alteration in T cell/macrophage ratio may reveal lymphocyte proliferation specific for the triggering antigen in reactive arthritis. *Scand J Immunol* 1992 Sep; 36(3): 427-34
529. Sieper J, Braun J, Brandt J, Miksits K, Heesemann J, Laitko S, Sorensen H, Distler A, Kingsley G. Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis. *J Rheumatol* 1992 Aug; 19(8): 1236-42
530. Sieper J, Braun J. Reactive arthritis: pathogenesis, diagnosis and therapy. *Z Aertzt Fortbild (Jena)* 1992 Mar 10; 86(5): 237-40
531. Braun J, Sieper J, Schulte KL, Thiel E, Janitschke K. Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus. *Clin Rheumatol* 1991 Dec; 10(4): 445-8
532. Braun J, Sieper J, Schwarz A, Keller F, Heitz J, von Ameln H. Severe lupus crisis with agranulocytosis and anuric renal failure due to a mesangial lesion (WHO IIB) - successful treatment with cyclophosphamide pulse followed by plasmapheresis. *Br J Rheumatol* 1991 Aug; 30(4): 312-3